References

Probst S, Saini C, Gschwind G Prevalence and incidence of venous leg ulcers—a systematic review and meta-analysis. Int Wound J. 2023; 20:(9)3906-3921 https://doi.org/10.1111/iwj.14272

Bonkemeyer Millan S, Gan R, Townsend PE Venous ulcers: diagnosis and treatment. Am Fam Physician. 2019; 100:(5)298-305

Raffetto JD Pathophysiology of chronic venous disease and venous ulcers. Surg Clin North Am. 2018; 98:(2)337-347 https://doi.org/10.1016/j.suc.2017.11.002

Aleksandrowicz H, Owczarczyk-Saczonek A, Placek W Venous leg ulcers: Advanced therapies and new technologies. Biomedicines. 2021; 9:(11) https://doi.org/10.3390/biomedicines9111569

Falanga V, Sabolinski M A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999; 7:(4)201-207 https://doi.org/10.1046/j.1524-475X.1999.00201.x

Kogan S, Sood A, Granick MS Wounds. 2018; 30:(6)168-173

O'Donnell TF, Passman MA, Marston WA Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2014; 60:3S-59S https://doi.org/10.1016/j.jvs.2014.04.049

Lin X, Lee CG, Casale ES, Shih JCH Purification and characterization of a keratinase from a feather-degrading Bacillus licheniformis strain. Appl Environ Microbiol. 1992; 58:(10)3271-3275 https://doi.org/10.1128/aem.58.10.3271-3275.1992

Rouse JG, Van Dyke ME A review of keratin-based biomaterials for biomedical applications. Materials. 2010; 3:(2)999-1014 https://doi.org/10.3390/ma3020999

Pechter PM, Gil J, Valdes J Keratin dressings speed epithelialization of deep partial-thickness wounds. Wound Repair Regen. 2012; 20:(2)236-242 https://doi.org/10.1111/j.1524-475X.2012.00768.x

Waters M, VandeVord P, Van Dyke M Keratin biomaterials augment anti-inflammatory macrophage phenotype in vitro. Acta Biomater. 2018; 66:213-223 https://doi.org/10.1016/j.actbio.2017.10.042

Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M Keratins and the keratinocyte activation cycle. J Invest Dermatol. 2001; 116:(5)633-640 https://doi.org/10.1046/j.1523-1747.2001.01327.x

Ramey-Ward AN, Walthall HP, Smith S, Barrows TH Human keratin matrices promote wound healing by modulating skin cell expression of cytokines and growth factors. Wound Repair Regen. 2024; 32:(3)257-267 https://doi.org/10.1111/wrr.13137

Konop M, Rybka M, Drapała A Keratin biomaterials in skin wound healing, an old player in modern medicine: a mini review. Pharmaceutics. 2021; 13:(12) https://doi.org/10.3390/pharmaceutics13122029

Ye W, Qin M, Qiu R, Li J Keratin-based wound dressings: from waste to wealth. Int J Biol Macromol. 2022; 211:183-197 https://doi.org/10.1016/j.ijbiomac.2022.04.216

Rice JB, Desai U, Cummings AK Burden of venous leg ulcers in the United States. J Med Econ. 2014; 17:(5)347-356 https://doi.org/10.3111/13696998.2014.903258

Barnsbee L, Cheng Q, Tulleners R Measuring costs and quality of life for venous leg ulcers. Int Wound J. 2019; 16:(1)112-121 https://doi.org/10.1111/iwj.13000

Norman G, Westby MJ, Rithalia AD Dressings and topical agents for treating venous leg ulcers. Cochrane Database Syst Rev. 2018; 6 https://doi.org/10.1002/14651858.CD012583.pub2

Rajhathy EM, Murray HD, Roberge VA, Woo KY Healing rates of venous leg ulcers managed with compression therapy. J Wound Ostomy Continence Nurs. 2020; 47:(5)477-483 https://doi.org/10.1097/WON.0000000000000693

Serena TE, Orgill DP, Armstrong DG A multicenter, randomized, controlled, clinical trial evaluating dehydrated human amniotic membrane in the treatment of venous leg ulcers. Plast Reconstr Surg. 2022; 150:(5)1128-1136 https://doi.org/10.1097/PRS.0000000000009650

Bain MA, Thibodeaux KT, Speyrer MS Effect of native type I collagen with polyhexamethylene biguanide antimicrobial on wounds: interim registry results. Plast Reconstr Surg Glob Open. 2019; 7:(6) https://doi.org/10.1097/GOX.0000000000002251

Koullias G, Bain M, Thibodeaux K, Sabolinski M A prospective noninterventional study of type I collagen matrix plus polyhexamethylene biguanide antimicrobial for the treatment of venous leg ulcers: a secondary analysis. Wound Manag Prev. 2022; 68:(6)11-17 https://doi.org/10.25270/wmp.2022.6.1117

Koullias GJ Efficacy of the application of a purified native collagen with embedded antimicrobial barrier followed by a placental allograft on a diverse group of nonhealing wounds of various etiologies. Wounds. 2021; 33:(1)20-27 https://doi.org/10.25270/wnds/2021.2027

Fearing BV, Van Dyke ME In vitro response of macrophage polarization to a keratin biomaterial. Acta Biomater. 2014; 10:(7)3136-3144 https://doi.org/10.1016/j.actbio.2014.04.003

Piipponen M, Li D, Landén NX The immune functions of keratinocytes in skin wound healing. Int J Mol Sci. 2020; 21:(22) https://doi.org/10.3390/ijms21228790

Patel GK, Wilson CH, Harding KG Numerous keratinocyte subtypes involved in wound re-epithelialization. J Invest Dermatol. 2006; 126:(2)497-502 https://doi.org/10.1038/sj.jid.5700101

El Ghalbzouri A, Hensbergen P, Gibbs S Fibroblasts facilitate re-epithelialization in wounded human skin equivalents. Lab Invest. 2004; 84:(1)102-112 https://doi.org/10.1038/labinvest.3700014

Wang S, Taraballi F, Tan LP, Ng KW Human keratin hydrogels support fibroblast attachment and proliferation in vitro. Cell Tissue Res. 2012; 347:(3)795-802 https://doi.org/10.1007/s00441-011-1295-2

Watt SM, Pleat JM Stem cells, niches and scaffolds: Applications to burns and wound care. Adv Drug Deliv Rev. 2018; 123:82-106 https://doi.org/10.1016/j.addr.2017.10.012

Chilosi M, Doglioni C, Murer B, Poletti V Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010; 27:(1)7-18

Wyles SP, Dashti P, Pirtskhalava T A chronic wound model to investigate skin cellular senescence. Aging (Albany NY). 2023; 15:(8)2852-2862 https://doi.org/10.18632/aging.204667

Wilcox JR, Carter MJ, Covington S Frequency of debridements and time to heal: a retrospective cohort study of 312 744 wounds. JAMA Dermatol. 2013; 149:(9)1050-1058 https://doi.org/10.1001/jamadermatol.2013.4960

Armstrong DG, Orgill DP, Galiano RD A multicentre clinical trial evaluating the outcomes of two application regimens of a unique keratin-based graft in the treatment of Wagner grade one non-healing diabetic foot ulcers. Int Wound J. 2024; 21:(9) https://doi.org/10.1111/iwj.70029

Lantis JC, Marston WA, Farber A The influence of patient and wound variables on healing of venous leg ulcers in a randomized controlled trial of growth-arrested allogeneic keratinocytes and fibroblasts. J Vasc Surg. 2013; 58:(2)433-439 https://doi.org/10.1016/j.jvs.2012.12.055

Bhatt P, Bennett E, Molden S Case studies. J Wound Care. 2023; 32:S13-S31 https://doi.org/10.12968/jowc.2023.32.Sup3b.S13

Ramey-Ward A, Chatelain R Use of a novel human keratin matrix improves healing rates in diabetic lower extremity wounds. Wounds. 2024; 36:(6)183-188 https://doi.org/10.25270/wnds/23139

Human keratin matrix in addition to standard of care accelerates healing of venous ulcers: a case series

02 December 2024
Volume 8 · Issue 3

Abstract

Objective:

Venous leg ulcers (VLUs) are often large and complicated wounds that, despite combinations of advanced wound care techniques and systemic treatment of underlying vascular issues, take many months to heal and have high rates of recurrence. In this study, we investigated the efficacy of a novel wound care solution—human keratin matrix (HKM).

Method:

A case series of VLUs were treated with HKM in conjunction with indicated vascular intervention and standard of care (SoC) procedures. For analysis, these wounds were divided into very large (>200cm2) and smaller (<35cm2) wounds.

Results:

The cohort comprised 16 VLUs (very large=7; smaller=9). Very large VLUs were reduced in size by an average of 71% within 10 weeks, and showed a 50% size reduction within four applications of HKM. Smaller VLUs reduced by 50% in size within the first three weeks of treatment, and 88.9% of these wounds healed completely with an average of 4.5 HKM applications over an average of 6.5 weeks.

Conclusion:

The results of this series highlight the potential of HKM, in combination with indicated systemic interventions and SoC, as an effective treatment for hard-to-heal (chronic) VLUs, even in very large wounds.

Venous leg ulcers (VLUs) are hard-to-heal (chronic) lower extremity wounds with high prevalence, affecting 1–3% of the US population.1 Insight into the pathogenesis of VLUs has increased significantly in the last two decades. VLUs are primarily caused by venous hypertension, in patients with genetic predisposition and coexistence of other risk factors, such as obesity, ageing and low levels of physical activity.2 These lead to chronic inflammation, causing red and white blood cell extravasation into the dermis and secretion of numerous proinflammatory cytokines. Skin break and ulceration at these areas soon follows.3 VLUs are often large with an irregular shape, and are characterised by multiple episodes of infection, drainage and cellulitis.2,3,4 Many patients with VLUs also have coexisting diabetes, obesity and other comorbidities. Often these VLUs are mixed aetiology ulcerations of primarily venous origin.

Register now to continue reading

Thank you for visiting Wound Central and reading some of our peer-reviewed resources for wound care professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Access to clinical or professional articles

  • New content and clinical updates each month